Global Eye Melanoma Market: Increasing Cases of Eye Cancer and Advancements in Treatment Methods Drive Market Growth

The global eye melanoma market size was USD 4.35 billion in 2022 and is expected to register a revenue CAGR of 8.3% during the forecast period. The global eye melanoma market is witnessing notable growth due to the rising prevalence of eye cancers, innovative treatment solutions, and technological advancements in screening and diagnosis. Eye melanoma, though rare, is the most common type of primary eye cancer in adults and has become a significant area of concern within the ophthalmology sector.

According to the American Society of Clinical Oncology (ASCO), eye melanoma accounts for 3% to 5% of all melanoma cases. The increasing number of eye cancer cases worldwide, primarily linked to factors such as the prolonged use of electronic devices emitting harmful UV radiation, is one of the major drivers for this market's growth. People over the age of 60 are particularly vulnerable, spending several hours a day on electronic gadgets, which may contribute to the rise in eye melanoma cases.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/2709

Advancements in Treatment and Biomarker Use Boost Market Growth

Recent advancements in medical technology, including the approval of new treatments, have further fueled growth in the eye melanoma market. For example, the U.S. Food and Drug Administration (FDA) approved the HEPZATO KIT (melphalan/Hepatic Delivery System) in August 2023, a significant development for treating uveal melanoma, a form of eye melanoma that spreads to the liver.

Another key trend propelling the market is the growing use of biomarkers in the diagnosis and treatment of eye melanoma. Blood biomarkers, such as circulating tumor DNA (ctDNA), are gaining prominence, enabling more accurate tracking of disease progression. Technological advancements have also enabled the identification of new biomarkers, which play a crucial role in early detection and personalized treatment plans.

Challenges Facing the Market

Despite the advancements, several challenges are hindering market growth. The high cost of treatments, combined with a lack of awareness about the early signs of eye cancer, limits access to timely interventions, especially among middle-income populations. Additionally, in developing and underdeveloped regions, a shortage of properly trained healthcare professionals capable of using advanced screening tools further restricts market expansion.

Uveal Melanoma Segment Dominates the Market

Eye melanoma primarily affects the uveal tract, with around 95% of all eye melanoma cases originating in this region. Uveal melanoma can lead to partial or complete vision loss and may spread to other parts of the body, most commonly the liver. The uveal melanoma segment dominated the market in 2022 and is expected to maintain its leading position due to its high incidence rate and severe impact on vision.

Meanwhile, conjunctival melanoma, though less common, is expected to grow rapidly over the coming years. This type of eye melanoma affects the membrane covering the white part of the eye and can be more aggressive, spreading to nearby regions, including lymph nodes and other tissues.

Radiation Therapy Leads Among Treatment Methods

In terms of treatment, radiation therapy accounted for the largest share of the market in 2022. This treatment method is preferred for its ability to target cancerous cells while preserving surrounding healthy tissue, making it particularly effective for ocular cancers. Radiation therapy is often used as a non-invasive alternative to surgery, especially for tumors in challenging locations.

Get a Discount On The Purchase Of This Report @ https://www.emergenresearch.com/request-discount/2709

 Hospitals and Clinics as Major End-Use Hubs

Hospitals and clinics emerged as the dominant end-use segment in 2022. Their extensive medical infrastructure, advanced diagnostic capabilities, and specialized oncology departments make them the primary choice for patients seeking treatment for eye melanoma. The multidisciplinary approach, involving ophthalmologists, oncologists, and radiologists, is crucial for providing comprehensive care and tailoring treatment plans to individual needs.

As the demand for advanced treatment solutions and early diagnostic methods continues to grow, hospitals and clinics are expected to play a pivotal role in addressing the evolving needs of eye melanoma patients.

Eye Melanoma Top Companies and Competitive Landscape

The global eye melanoma market is fairly fragmented, with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective eye melanoma solutions.

Some major players included in the global eye melanoma market report are:

AbbVie Inc.

Amgen Inc.,

Astra Zeneca plc

Bayer AG

Bristol-Myers Squibb Company

Carl Zeiss AG

Castle Biosciences, Inc.

Eli Lilly & Co.

Hoffmann-La Roche Ltd,

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Johnson & Johnson Services, Inc.

Koninklijke Philips N.V,

Merck

Novartis AG

Optovue Incorporated

Pfizer, Inc.

Roche

Sanofi

Siemens

Spectrum Pharmaceuticals, Inc.

Others

For more informative information, please visit us @ https://www.emergenresearch.com/industry-report/eye-melanoma-market

Eye Melanoma Latest Industry Updates

On 31 October 2023, The FDA has approved the Swiss company iOnctura to explore a new drug application involving Roginolisib (IOA-244) for the treatment of various conditions, including solid and hematologic malignancies such as uveal melanoma. This approval reflects the company's commitment to advancing research in the field.

On 22 June 2023, IDEAYA Biosciences, Inc. announced the first reported case of uveal melanoma (UM) patient who was treated with single-agent darovasertib as neoadjuvant therapy and was spared enucleation in an Investigator Sponsored Trial (IST).

For the purpose of this report, Emergen Research has segmented the global eye melanoma market on the basis of site, treatment, end-use, and region:

Site Outlook (Revenue, USD Billion; 2019-2032)

Uvea

Conjunctiva

Sclera

Retina

Others

Treatment Outlook (Revenue, USD Billion; 2019-2032)

Radiation Therapy

Surgery

Laser Therapy

Immunotherapy

Others

End-Use Outlook (Revenue, USD Billion; 2019-2032)

Hospital and Clinics

Academic Institutes

Others

Regional Outlook (Revenue, USD Billion; 2019-2032)

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Benelux

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Rest of APAC

Latin America

Brazil

Rest of LATAM

Middle East & Africa

Saudi Arabia

UAE

South Africa

Turkey

Rest of MEA

Make Payment [Buy your Exclusive copy] @ https://www.emergenresearch.com/select-license/2709

Look Over transcripts provided by Emergen Research

Eye Melanoma Market Size@ https://www.emergenresearch.com/industry-report/eye-melanoma-market/market-size

Eye Melanoma Market Share@ https://www.emergenresearch.com/industry-report/eye-melanoma-market/market-share

Eye Melanoma Market Trends@  https://www.emergenresearch.com/industry-report/eye-melanoma-market/market-trends

Eye Melanoma Regional Market Demand@ https://www.emergenresearch.com/industry-report/eye-melanoma-market/regional-market-demand

Eye Melanoma Market Analysis@ https://www.emergenresearch.com/industry-report/eye-melanoma-market/market-analysis

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

About Us:

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.